New molecular targets in melanoma

Current Opinion in Oncology

Volumn 16, Issue 2, 2004, Pages 150-154

  Flaherty, Keith T ^a   Brose, Marcia S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Melanoma; Metastasis; Molecular targets

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; BEVACIZUMAB; CARBOPLATIN; CRAF PROTEIN; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; GUANOSINE TRIPHOSPHATE; IMATINIB; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR INHIBITOR; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; PROTEIN P16; PROTEIN P53; RAF PROTEIN; RAS PROTEIN; RECEPTOR BLOCKING AGENT; SORAFENIB; TEMOZOLOMIDE; TEMSIROLIMUS; THALIDOMIDE; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR;

ADVANCED CANCER; AMINO ACID SUBSTITUTION; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BRAF GENE; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER SURVIVAL; CELL FUNCTION; CLINICAL TRIAL; DRUG MECHANISM; DRUG TARGETING; GENE MUTATION; HUMAN; MELANOMA; METASTASIS; MITOSIS INHIBITION; MONOTHERAPY; ONCOGENE; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SKIN CANCER; TRANSLATION REGULATION; TREATMENT PLANNING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; ENZYME INHIBITORS; HUMANS; MELANOMA; MITOGEN-ACTIVATED PROTEIN KINASES; OLIGONUCLEOTIDES; PROTO-ONCOGENE PROTEINS C-RAF; RAS PROTEINS; SKIN NEOPLASMS;

EID: 1642569629     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200403000-00012     Document Type: Review

References (33)

1. Sun W, Schuchter LM: Metastatic melanoma. Curr Treat Options Oncol 2001, 2:193-202.
2. Davies H, Bignell GR, Cox C, et al.: Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954. Epub 2002 Jun 09.
3. Kamb A, Gruis NA, Weaver-Feldhaus J, et al.: Cell cycle regulator potentially involved in genesis of many tumor types. Science 1994, 264:436-440.
4. Soengas MS, Capodieci P, Polsky D, et al.: Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001, 409:207-211.
5. Maldonado JL, Patel H, Fridlyand J, et al.: BRAF mutations in melanoma vary with anatomic site, are not associated with outcome and go along with increased copy numbers of the mutated allele [abstract]. Proc AACR 2003, 44:abstract# R5802.
6. Tsao H, Zhang X, Fowlkes K, et al.: Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines. Cancer Res 2000, 60:1800-1804.
7. Adjei AA, Erlichman C, Davis JN, et al.: A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. Cancer Res 2000, 60:1871-1877.
8. Karp JE, Lancet JE, Kaufmann SH, et al.: Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood 2001, 97:3361-3369.
9. Brose MS, Volpe P, Feldman M, et al.: BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002, 62:6997-7000.
10. Choi Y-J, Fanidi A, White S, et al.: The novel Raf inhibitor BAY 43-9006 blocks signaling and proliferation in BRAF mutant and wild-type melanoma and colorectal tumor cell lines [abstract]. Proc AACR 2003, 44:138, abstract #720.
11. Strumberg D, Voliotis D, Moeller JG, et al.: A clinical phase I and biomarker study of the Raf kinase inhibitor BAY 43-9006: preliminary evidence of activity in patients with advanced solid tumors [abstract]. Eur J Cancer 2002, 38(Suppl 7):53, abstract #167.
12. Ratain MJ, O'Dwyer P, Stadler W, et al.: A phase II study of BAY 43-9006 using the randomized discontinuation design in patients with advanced refractory cancer. Proc Second International Signal Transduction Meeting, abstract #024, 2003.
13. Flaherty KT, Schuchter LM, Tuveson D, et al.: Phase I trial of BAY 43-9006 in combination with carboplatin and paclitaxel [abstract]. Proc Am Soc Clin Oncol 2003, 22:710, abstract 2854.
14. Hodi FS, Soiffer RJ, Clark J, et al.: Phase II study of paclitaxel and carboplatin for malignant melanoma. Am J Clin Oncol 2002, 25:283-286.
15. Wang HG, Rapp UR, Reed JC: Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell 1996, 87:629-638.
16. Stretch JR, Gatter KC, Ralfkiaer E, et al.: Expression of mutant p53 in melanoma. Cancer Res 1991, 51:5976-5979.
17. Saenz-Santamaria MC, McNutt NS, Shea CR: Immunohistochemical expression of retinoblastoma protein in cutaneous melanomas. Br J Dermatol 1995, 133:890-895.
18. Jansen B, Wacheck V, Heere-Ress E, et al.: Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 2000, 356:1728-1733.
19. Webb A, Cunningham D, Cotter F, et al.: BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 1997, 349:1137-1141.
20. http://www.genta.com/Genta/InvestorRelation/2003/press_20030910_1. html
21. Tang L, Tron VA, Reed JC, et al.: Expression of apoptosis regulators in cutaneous malignant melanoma. Clin Cancer Res 1998, 4:1865-1871.
22. O'Dwyer PJ, Stevenson JP, Gallagher M, et al.: c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A). Clin Cancer Res 1999, 5:3977-3982.
23. Belli B, Deckwerth T, Al Assaad S, et al.: A-385358, a potent Bcl-xL/Bcl-2 antagonist induces apoptosis in tumor cell lines [abstract]. Proc AACR 2003, 44, abstract LB-150.
24. Busca R, Bertolotto C, Ortonne JP, et al.: Inhibition of the phosphatidylinositol 3-kinase/p70(S6)-kinase pathway induces B16 melanoma cell differentiation. J Biol Chem 1996, 271:31824-31830.
25. Peralba JM, DeGraffenried L, Friedrichs W, et al.: Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin Cancer Res 2003, 9:2887-2892.
26. Chan S, Scheulen ME, Johnston S: Phase 2 study of two dose levels of CCI-779 in locally advanced or metastatic breast cancer (MBC) failing prior anthracycline and/or taxane regimens [abstract]. Proc Am Soc Clin Oncol 2003, 22:193, abstract 774.
27. Kashani-Sabet M, Sagebiel RW, Ferreira CM, et al.: Tumor vascularity in the prognostic assessment of primary cutaneous melanoma. J Clin Oncol 2002, 20:1826-1831.
28. Ugurel S, Rappl G, Tilgen W, et al.: Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 2001, 19:577-583.
29. Eisen T, Boshoff C, Mak I, et al.: Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 2000, 82:812-817.
30. Hwu WJ, Krown SE, Menell JH, et al.: Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J Clin Oncol 2003, 21:3351-3356.
31. Carson WE, Biber J, Shah N: A phase 2 trial of a recombinant humanized monoclonal anti-vascular endothelial growth factor (VEGF) antibody in patients with malignant melanoma [abstract]. Proc Am Soc Clin Oncol 2003, 22:715, abstract 2873.
32. Pietras K, Rubin K, Sjoblom T, et al.: Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 2002, 62:5476-5484.
33. Bergers G, Song S, Meyer-Morse N, et al.: Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003, 111:1287-1295.